03:14 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

United Therapeutics' Orenitram delays disease progression in Phase III for PAH

United Therapeutics Corp. (NASDAQ:UTHR) said Orenitram treprostinil met the primary endpoint in the double-blind, international Phase III FREEDOM-EV trial in 690 pulmonary arterial hypertension (PAH) patients on background oral monotherapy. Thrice-daily oral Orenitram significantly delayed...
18:42 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Phase III of Bellerophon's INOpulse for PAH stopped for futility

Bellerophon Therapeutics Inc. (NASDAQ:BLPH) said a DMC recommended stopping for futility the Phase III INOvation-1 trial of INOpulse to treat pulmonary arterial hypertension (PAH). A prespecified interim analysis of the first 75 patients who completed 16...
18:13 , Jul 27, 2018 |  BC Week In Review  |  Financial News

Liquidia prices $50M IPO

Liquidia Technologies Inc. (NASDAQ:LQDA) raised $50 million on July 25 through the sale of 4.5 million shares at $11 in an IPO underwritten by Jefferies, Cowen, Needham and Wedbush PacGrow. Liquidia priced the offering at...
17:02 , Jul 27, 2018 |  BC Week In Review  |  Company News

Milligan, Martin leaving Gilead

Gilead Sciences Inc. (NASDAQ:GILD) said President and CEO John Milligan will step down at year end. The company's board is searching for a successor. Milligan has been at Gilead for 28 years. He became CEO in...
15:27 , Jul 26, 2018 |  BC Extra  |  Financial News

Liquidia prices $50M IPO

Liquidia Technologies Inc. (NASDAQ:LQDA) added $0.10 to $11.10 on Thursday after raising $50 million through the sale of 4.5 million shares at $11 in an IPO underwritten by Jefferies, Cowen, Needham and Wedbush PacGrow. Liquidia...
01:05 , Jul 26, 2018 |  BC Extra  |  Company News

Milligan, Martin leaving Gilead

Gilead Sciences Inc. (NASDAQ:GILD) said President and CEO John Milligan will step down at year end. The company's board is searching for a successor. Milligan has been at Gilead for 28 years. He became CEO in...
16:03 , Jul 20, 2018 |  BC Week In Review  |  Company News

Roivant establishes new business units, launches PAH company

Roivant Sciences GmbH (Basel, Switzerland) said it created two business units, Roivant Pharma and Roivant Health, and launched pulmonary arterial hypertension (PAH) company Altavant. Roivant Pharma will focus on "end-to-end biopharmaceutical company creation in new therapeutic...
18:20 , Jun 15, 2018 |  BC Week In Review  |  Company News

Denovo gains IP from Stanford to develop lead program for new indication

Denovo Biopharma LLC (San Diego, Calif.) received exclusive, worldwide rights to IP from the Stanford University School of Medicine (Stanford, Calif.) that the biotech said will allow it to develop lead program enzastaurin (DB102) for...
15:16 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Hypertension Cell culture and rat studies suggest nanoparticles loaded with cerivastatin could help treat pulmonary arterial hypertension (PAH) without the cytotoxicity of free cerivastatin. In a rat model of PAH, intratracheal administration of liposomes...
15:25 , May 4, 2018 |  BC Week In Review  |  Company News

United Therapeutics acquiring SteadyMed for $216M

United Therapeutics Corp. (NASDAQ:UTHR) is acquiring SteadyMed Ltd. (NASDAQ:STDY) for $4.46 in cash per share, plus an additional $2.63 per share tied to milestones, in a deal the partners said is valued at $216 million....